Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.
Nat Rev Urol
; 20(7): 420-433, 2023 07.
Article
in En
| MEDLINE
| ID: mdl-36928615
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
Type of study:
Guideline
Language:
En
Journal:
Nat Rev Urol
Year:
2023
Type:
Article
Affiliation country:
United States